Samsungbioepis Co,.Ltd Sustainability Profile
Samsung Bioepis Co., Ltd., a leading biopharmaceutical company headquartered in South Korea (KR), is renowned for its innovative approach in the biosimilars industry. Founded in 2012, the company has rapidly established itself as a key player in the global market, focusing on the development and commercialisation of high-quality biosimilars and biologics. With a strong presence in major operational regions including North America, Europe, and Asia, Samsung Bioepis offers a diverse portfolio of products that includes biosimilars for oncology and autoimmune diseases. Their commitment to rigorous research and development, combined with advanced manufacturing capabilities, sets them apart in a competitive landscape. Notable achievements include strategic partnerships with global pharmaceutical leaders, enhancing their market position and expanding access to affordable treatments. Samsung Bioepis continues to drive innovation, making significant contributions to the healthcare sector.
DitchCarbon Score
How does Samsungbioepis Co,.Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsungbioepis Co,.Ltd's score of 42 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Samsungbioepis Co,.Ltd's reported carbon emissions
In 2024, Samsungbioepis Co., Ltd. reported total carbon emissions of approximately 66.7 million kg CO2e. This figure includes Scope 1 emissions of about 1.2 million kg CO2e and Scope 2 emissions of approximately 5.1 million kg CO2e. The company has not disclosed Scope 3 emissions in detail for 2024, but previous data indicates significant contributions from categories such as purchased goods and services, which accounted for about 37.8 million kg CO2e. Samsungbioepis has set ambitious climate commitments, aiming to reduce GHG emissions by 32% from a 2022 baseline by the year 2030. This target applies to both Scope 1 and Scope 2 emissions, reflecting a strong commitment to mitigating its carbon footprint. The emissions data for 2023 shows a total of approximately 6.3 million kg CO2e, with Scope 1 at about 1.2 million kg CO2e and Scope 2 at approximately 5.1 million kg CO2e. In 2022, the total emissions were around 6.1 million kg CO2e, indicating a slight increase in emissions over the years. It is important to note that emissions data for 2023 and 2022 has been cascaded from the parent company, Samsung Biologics Co., Ltd., which is responsible for the broader corporate sustainability initiatives. Samsungbioepis is committed to transparency and continuous improvement in its environmental performance, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,433,412 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,296,110 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
How Carbon Intensive is Samsungbioepis Co,.Ltd's Industry?
How Carbon Intensive is Samsungbioepis Co,.Ltd's Location?
Samsungbioepis Co,.Ltd's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Top Scope 3 Categories
Samsungbioepis Co,.Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Samsungbioepis Co,.Ltd has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
